Czechia· CZ-0210993
ZERBAXA
A ceftolozan und beta-lactamase-inhibitor product containing ceftolozane sulfate + tazobactam sodium, registered in Czechia by Merck Sharp & Dohme B.V., Haarlem. The same ATC class is registered in 11 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Ceftolozan und beta-lactamase-inhibitor is registered in 11 of 19 countries.
Countries holding a registration under ATC J01DI54 (ceftolozan und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 7 of them publish a price we can compare per daily dose
Ceftolozan und beta-lactamase-inhibitor · ATC J01DI54
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- CEFTOLOZANE SULFATE + TAZOBACTAM SODIUM
- Manufacturer
- Merck Sharp & Dohme B.V., Haarlem
- Country
- Czechia (CZ)
- ATC code
- J01DI54
- ATC class
- Ceftolozan und Beta-Lactamase-Inhibitor
- Defined daily dose
- 3 g, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ceftolozan und beta-lactamase-inhibitor in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandZerbaxaMerck Sharp & Dohme B.V.
- CanadaZERBAXAMERCK CANADA INC
- SwitzerlandZerbaxa 1.5 g, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMSD Merck Sharp & Dohme AG
- SpainZERBAXA 1 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandZerbaxaMerck Sharp & Dohme B.V.
- FranceZERBAXA 1 g/0,5 g, poudre pour solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomZerbaxa 1g/0.5g powder for concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IrelandZerbaxa 1 g/0.5 g powder for concentrate for solution for infusionMerck Sharp & Dohme BV,
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zerbaxa
- Liechtenstein · Zerbaxa
- Norway · Zerbaxa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/37161cfe-d32a-424a-9ee4-da10acf5d3f6 GET /v1/drugs/37161cfe-d32a-424a-9ee4-da10acf5d3f6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF PLV CSL",
"source": "sukl",
"strength": "1G/0,5G",
"pack_size": "10",
"substance": "CEFTOLOZANE SULFATE + TAZOBACTAM SODIUM",
"cz_kod_sukl": "0210993",
"product_type": "CH",
"substance_codes": "20879,14176",
"registration_state": "R",
"registration_number": "EU/1/15/1032/001"
}See everything about ceftolozan und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.